| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 549.24 | 1.6% | 27.5% |
| Total Income | 549.77 | 1.8% | 26.6% |
| Expenditure | 569.51 | 2.8% | 22.6% |
| PBT | -19.75 | 23.6% | 65.3% |
| Net Profit | -15.24 | 21.1% | 63.4% |
| OPM | 1.88% | 1.79pp | 9.91pp |
| NPM | -2.77% | 0.68pp | 6.81pp |
| EPS | -2.98 | 178.8% | 136.7% |
Chemicals Beat Can't Escape Consolidated Loss
Bio-chemicals beat guidance and margins expanded, but consolidated net loss of ₹15.2 Cr persists despite 27.5% revenue growth. Sugar and ethanol losses of ₹19.3 Cr EBITDA are consuming profits — the real question is whether debottlenecking can overcome it.
₹204.2 Cr
Beat ₹190 Cr guidance · +38.8% YoY
10.8%
+60 bps YoY · Up from 10.2%
-₹15.2 Cr
Narrowed 63% from -₹41.6 Cr YoY · Still loss
-₹19.3 Cr
Q2 segment drag · Better than -₹23.1 Cr YoY
The split tells the story. Godavari's bio-chemicals business beat guidance by ₹14.2 Cr and expanded margins by 60 basis points — exactly the debottlenecking story management has been selling. But the consolidated result is a loss of ₹15.2 Cr, despite revenue growth of 27.5%. The reason: the sugar and ethanol segment lost ₹19.3 Cr in EBITDA in Q2 alone. Chemicals are roaring; the rest of the business is not just quiet, it's bleeding.
Where the profit went
The sugar and ethanol business is seasonal — management says Q3 and Q4 are typically profitable — but the scale of Q2 loss (₹19.3 Cr EBITDA) is material and ongoing. Sugar revenue fell slightly due to monsoon failure in Maharashtra and Karnataka and government restrictions on diverting sugarcane juice to ethanol. Ethanol, despite a new grain-based distillery commissioned in Q1 (800 kL/day total capacity), faced feedstock constraints and weak pricing. Management expects H2 recovery, but no quantified guidance was offered.
Management claims vs. what holds up
Bio-chemicals revenue ₹204.2 Cr beat ₹190 Cr guidance
Delivered ₹204.2 Cr vs ₹190 Cr; +7.5% beat, +38.8% YoY growth vs ₹147 Cr Q2 FY26
Supported
Bio-chemicals EBITDA margin improved to 10.8%
₹22.1 Cr EBITDA ÷ ₹204.2 Cr revenue = 10.83%; up 60 bps YoY
Supported
Consolidated net loss narrowed to ₹15.2 Cr from ₹41.6 Cr YoY
Q2 FY26 loss -₹41.6 Cr, Q2 FY27 loss -₹15.2 Cr; 63.4% improvement. Still loss, not profit.
Supported (with context)
₹240 Cr quarterly chemicals target by FY28 is achievable
Currently ₹204.2 Cr; requires 17.6% CAGR over ~5 quarters. Dependent on ₹25 Cr capex not yet proven.
Overstated—projection only
Consolidated operations moving toward profitability
Consolidated NPM -2.8% in Q2 FY27. Sugar loss ₹19.3 Cr EBITDA. No PAT timeline disclosed.
Contradicted
What changed on this call
Bio-chemicals beat Q2 guidance by ₹14.2 Cr (₹204.2 vs ₹190 Cr); driven by debottlenecking progress and higher Hormuz-related pricing.
Consolidated loss narrowed 63% YoY but remains -₹15.2 Cr; no path to profitability timeline quantified.
₹240 Cr/qtr chemicals target by FY28 reaffirmed, not raised; same ₹25 Cr capex plan from Q1 guidance.
Grain-based distillery (200 kL/day) now operational; ethanol EBITDA improved to ₹10.6 Cr from ₹4.7 Cr YoY despite feedstock headwinds.
Sugar/ethanol segment loss persists (₹19.3 Cr EBITDA loss Q2) due to monsoon failure and government policy tightening on ethanol diversion.
The bull-bear ledger
Bio-chemicals beat Q2 guidance by ₹14.2 Cr; margins expanded 60 bps; debottlenecking strategy working as expected.
Strong chemicals growth (38.8% YoY) validates market demand for bio-based specialty chemicals; patent portfolio differentiates.
Multi-feedstock distillery (grain + cane) reduces single-feedstock risk; ethanol EBITDA doubled YoY to ₹10.6 Cr.
Near-term catalysts: DME pilot results March 2027, TNBC trials Q3 FY27, 20-25 new specialty chemicals launching April-Sept 2027.
Consolidated loss persists at -₹15.2 Cr despite 27.5% revenue growth; sugar/ethanol loss (₹19.3 Cr EBITDA) is material and ongoing.
No quantified consolidated profitability timeline; management deferred to H2 seasonality and vague ₹240 Cr target without credible path to PAT positive.
Feedstock and government policy volatility (monsoon, sugarcane diversion, grain prices) create headwinds management cannot fully control.
₹240 Cr/qtr target by FY28 is unproven; requires debottlenecking capex to deliver proportional revenue and margin gains.
How the street is positioned
The stock stands at ₹218.06, down 46.63% from its all-time high of ₹408.6 and trading below both the 50-day (₹227.96) and 200-day (₹269.24) moving averages. The trend is bearish; RSI sits at 46.7 (neutral), and volume is decreasing. This is not a stock finding support near its lows — it is a stock that has been rerated lower and lower as consolidated losses accumulated.
Ownership flows confirm the challenge. FII holdings collapsed from 0.98% in FY26 Q4 to 0.22% in FY27 Q1, a drop of 76 basis points in a single quarter. Domestic institutions remain steady at ~10%, and promoters hold firm at 63.31%, but the FII exit is a clear signal: foreign money is not waiting for the consolidated loss story to resolve. Bulk deals over the past six months show research and trading desks accumulating near ₹252 — a tactical trade, not a strategic vote of confidence.
The post-result market reaction appears muted (volume trending lower), suggesting the street views this as neither a relief bounce nor a capitulation flush. The chemicals beat is noted; the consolidated loss is priced in. The real re-rating will come only if management articulates a path to consolidated profitability, or if it delivers on ₹240 Cr chemicals run-rate in real time.
Ranked risks for a holder
Consolidated PAT negative despite 27.5% revenue growth
HighLosses are structural, not cyclical one-offs. No credible timeline to breakeven disclosed. Every quarter of loss erodes shareholder value and constrains capex flexibility.
Sugar/ethanol segment loss-making; feedstock and policy volatility uncontrollable
High₹19.3 Cr EBITDA loss Q2 driven by monsoon, government ethanol restrictions, grain price inflation. H2 recovery promised but not quantified.
Debottlenecking capex and ₹240 Cr target execution uncertain
Medium₹25 Cr capex deployed through 2027 must unlock ₹240 Cr/qtr run-rate. Q2 beat validates progress, but reaching ₹240 Cr requires sustained momentum and new product ramps.
Innovation timelines (DME March 2027, TNBC Q3) may not commercialize as expected
MediumTrials are early-stage; timelines to clinical approval, manufacturing, and revenue uncertain. TNBC is out-licensed (not owned by Godavari).
FII selling and valuation drawdown eroding equity story
MediumFII holders down 76 bps in one quarter; stock down 46% from ATH. Further multiple compression could trigger forced selling if loss persists.
What to watch next
1 · H2 FY27 sugar seasonality and segment turnaround
Management expects Q3/Q4 to be profitable seasonally. Watch for (a) actual sugar revenue and EBITDA in Q3 FY27 results, (b) whether monsoon recovery and improved feedstock availability narrow segment losses, and (c) whether multi-feedstock ethanol facility reduces drag.
2 · ₹25 Cr capex deployment and new specialty chemical ramp
Capex is supposed to unlock 20-25 new specialty chemicals and push bio-chemicals toward ₹240 Cr/qtr. Watch for (a) capex spend progress in FY27 H2, (b) new product launches materializing in April-Sept 2027 window, and (c) revenue contribution visible by Q3/Q4 FY27.
3 · DME pilot and TNBC trial outcomes
DME pilot results due March 2027; TNBC preliminary efficacy due Q3 FY27. Watch for (a) technical feasibility signals, (b) TNBC safety/efficacy data, and (c) out-licensing traction. Disappoint on both and near-term catalysts lose credibility.
The debate
Rating: Hold. For existing holders who believe in the chemicals thesis and can tolerate ongoing quarterly losses. For fresh entry, wait for either (a) a quantified consolidated profitability timeline with a date, or (b) two consecutive quarters of chemicals hitting ₹240+ Cr run-rate while sugar losses materially narrow to ₹5 Cr EBITDA or less. The ₹15.2 Cr consolidated loss is the number to track.
H2 FY27 consolidated net loss is the verdict: if it narrows to ₹10 Cr or less across Q3+Q4, the thesis holds. If it remains above ₹20 Cr, the sugar hedge failed and profitability is pushed to FY28 or later. Watch that number.
Chemicals boom masks consolidated loss drag
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Beat Q2 chemicals guidance (₹204 vs ₹190 Cr). Sugar losses persist; no FY27/FY28 consolidated profit target disclosed.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Godavari's bio-chemicals division delivered a beat (₹204.2 Cr vs ₹190 Cr guidance, +38.8% YoY) with expanding margins (10.8%, +60 bps), validating the debottlenecking strategy. However, consolidated loss remains material at -₹15.2 Cr (NPM -2.8%), dragged by a loss-making sugar/ethanol segment (₹19.3 Cr EBITDA loss). The ₹240 Cr quarterly chemicals target by FY28 is ambitious and unproven; management offered no credible profitability timeline for the overall business.
₹549.2 Cr
Revenue · +27.5% YoY₹-15.2 Cr
Reported PAT · +null% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Bio-chemicals revenue ₹204.2 Cr, beat ₹190 Cr guidance
METDelivered ₹204.2 Cr vs ₹190 Cr expected; +7.5% beat, +38.8% YoY growth vs Q2 FY26 ₹147 Cr
Bio-chemicals EBITDA margin improved to 10.8% from 10.2%
METEBITDA ₹22.1 Cr ÷ ₹204.2 Cr revenue = 10.83%, up 60 bps confirmed; +47% YoY in rupees
Consolidated net loss narrowed to ₹15.2 Cr from ₹41.6 Cr YoY
METQ2 FY26 loss -₹41.6 Cr, Q2 FY27 loss -₹15.2 Cr; 63.4% improvement in loss magnitude. Still loss, not profit.
₹240 Cr quarterly chemicals revenue achievable by FY28
OVERSTATEDCurrently ₹204.2 Cr; requires 17.6% CAGR over ~5 quarters. Dependent on ₹25 Cr debottlenecking investment not yet validated. Projection, not committed.
Consolidated operations moving toward profitability
MISSConsolidated NPM -2.8% in Q2 FY27 (vs -3.5% in H1 FY26 average). Sugar/ethanol segment lost ₹19.3 Cr EBITDA in Q2 (61% of revenue). No profit timeline disclosed.
Earnings quality
What changed since the last call
Bio-chemicals beat Q2 guidance by ₹14.2 Cr
UpgradeQ2 FY27 ₹190 Cr guidance → ₹204.2 Cr delivered. Driven by higher volumes from debottlenecking initiatives and crisis-driven Hormuz area sales. This is a beat this quarter, not a multiyear guidance raise.
Consolidated loss narrowed, not profitability achieved
NeutralLoss shrunk from -₹41.6 Cr (Q2 FY26) to -₹15.2 Cr (Q2 FY27), a 63.4% improvement in loss magnitude. But NPM remains -2.8%. No path to breakeven disclosed; management deferred to H2 seasonality.
₹240 Cr/qtr chemicals target timeline reaffirmed
NeutralSame FY28 target and ₹25 Cr investment reconfirmed from Q1 guidance. No acceleration or new milestones added. Debottlenecking in progress but not yet revenue-visible above Q2's ₹204 Cr.
Sugar/ethanol segment loss persists despite distillery commissioning
DowngradeQ2 FY27 sugar segment EBITDA loss ₹19.3 Cr (vs ₹23.1 Cr in Q2 FY26, improvement of ₹3.8 Cr). Grain-based distillery commissioned Q1, now operational, but ethanol economics weak due to feedstock constraints and monsoon failure in Maharashtra/Karnataka.
The Q&A
Moderate. Analysts pressed on profitability timeline, feedstock risks, and inventory volatility. Management held steady on strategy but offered hedges: 'H2 is seasonally stronger,' 'feedstock landscape evolving,' 'debottlenecking in progress.' Q&A was candid on challenges but vague on consolidated profit recovery.
Bio-chemicals guidance beat — Vivek Gupta, Star Investments
AnsweredCombination of increased volumes from debottlenecking investments done, and higher prices from Hormuz crisis. ₹204 Cr also includes ₹140 Cr legacy baseline (vs ₹147 Cr Q2 FY26), so net ₹60 Cr incremental from new chemicals and higher realization.
Profitability timeline and initiatives — Kranti, WealthMills Securities
AnsweredBio-chemicals will drive profitability (already ~90% of segment EBITDA from chemicals in H1). Sugar-ethanol is seasonal; H2 is profitable. DME pilot March 2027. TNBC trials starting soon (6-9 month preliminary results). ₹240 Cr/qtr target by FY28 will bring consolidated improvement.
Drug discovery capex and strategy — Nivesh Verma, Verxora Securities
AnsweredPreliminary efficacy budget ₹15-20 Cr. Not a pharma company, so will out-license molecule to pharma companies post-trials for clinical development. Strategy is to derisk early-stage and partner.
Feedstock and ethanol facility flexibility — Nivesh Verma, Verxora Securities
Answered800 kL/day total distillery capacity. Grain-based facility enables maize and rice processing; cane-based ethanol flexible. Government restricted sugarcane juice diversion to ethanol (favoring sugar); company adapting by using molasses, grain. Multi-feedstock strategy reduces mono-feedstock risk and aligns with government E20 blending goal.
Chemicals EBITDA margin and growth proportion — Hitesh Agarwal, Investment Partners
PartialIncremental margin comes from specialty chemicals (ethyl acetate, higher-volume molecules) and debottlenecking. ₹190 Cr→₹240 Cr progression expected to yield further margin expansion as scale improves and mix shifts to specialty products.
Inventory decline and working capital — Hitesh Agarwal, Investment Partners
AnsweredPurely seasonal. March (Q4) has peak sugar stocks; September (Q2) has lower stocks due to processing cycle. Chemical inventory grows pro-rata with business; nothing structural to read.
Feedstock procurement and agricultural strategy — Suhani Singh, ROS Capital
AnsweredMulti-feedstock strategy key. Working with farmers via Agriculture Research Station for high-yield varieties and regenerative practices. Maize prices high but locked in for ethanol blending via ENA (ethanol for OMCs). Sugar economics improving if prices move up due to tighter market. Rice sourcing via PCI scheme. Each feedstock has different economics; company optimizing mix.
Chemicals volume vs. realization and specialty share — Snehil Surana, Star Broking
AnsweredMix of both. ₹147 Cr Q2 FY26 → ₹204.2 Cr Q2 FY27 = ₹57 Cr net growth. Partly from existing chemicals scaling (volume + some price from debottlenecking benefit), partly from specialty chemical mix in H1 (52% of H1 revenue is specialty). New specialty chemicals launching April-September 2027 from ₹25 Cr capex will further shift mix.
Ethanol and sugar economics — Varun Mishra, SG Capital
PartialLong answer on feedstock dynamics. Grain prices can be high, but hedged via ENA (ethanol for OMCs) contracts. Sugar market expected to tighten due to reduced B-molasses diversion from ethanol policy; should support sugar price uplift. Monsoon risks persist; droughts likely every few years, but company diversifying feedstock to insulate.
Capex allocation and debottlenecking priority — Varun Mishra, SG Capital
Answered₹25 Cr is primarily bio-chemicals debottlenecking (acid base capacity, de-bottlenecking across 20-25 specialty chemicals). Ethanol facility optimizations are minor capex; major investments deferred pending larger off-take agreements from customers.
PAT profitability timeline — Varun Mishra, SG Capital
DodgedHistory shows Q3/Q4 are strong (seasonal sugar profitability). Company expects modest improvement in H2 FY27. PAT positive depends on sugar price realization and chemicals debottlenecking delivering on ₹240 Cr target by FY28. No specific FY year committed.
Grain-based distillery operational status — Snehil Surana, Star Broking
AnsweredCommissioned end of Q1 (end of June). Now operational to meet orders from oil companies for ethanol blending. Taking contracts, meeting delivery schedules. Facility operational and functional for ethanol-based program.
Guidance
Bio-based chemicals ₹240 Cr/quarter by FY28 (vs ₹204.2 Cr Q2 FY27)
MediumTarget supported by ₹25 Cr debottlenecking investment ongoing through 2027. Requires ~17.6% CAGR over next 5 quarters. Achieved in 20-25 new specialty chemical products.
Bio-chemicals EBITDA margin to improve toward double-digits as volume scales and product mix shifts to specialty
MediumCurrently 10.8% (Q2 FY27). Management expects incremental margin as ₹190 Cr→₹240 Cr progression scales and higher-value molecules ramp. No specific percentage target.
₹25 Cr capex for bio-chemicals debottlenecking and multi-feedstock ethanol facility optimization
High₹25 Cr debottlenecking capex announced Q1 FY27; deployed through H1-H2. Majority for bio-chemicals acid base and specialty capacity. Ethanol facility minor optimization ongoing.
Risks the call surfaced
Profitability & leverage
HighCompany lost ₹15.2 Cr in Q2 FY27 despite 27.5% revenue growth. Sugar/ethanol segment drag (₹19.3 Cr EBITDA loss) masks chemicals strength. Management deferred profitability recovery to 'H2' with no quantified target.
Feedstock & seasonality
HighMaharashtra/Karnataka drought affected sugar/ethanol production. Government restricted sugarcane juice diversion to ethanol, favoring sugar production. Grain prices volatile. Company mitigating via multi-feedstock facility, but economics depend on external supply/policy.
Execution & debottlenecking
MediumTarget ₹240 Cr/qtr bio-chemicals by FY28 assumes debottlenecking yields proportional revenue and margin gains. Q2 beat (₹204 vs ₹190 Cr) is step forward, but ₹240 Cr remains unproven projection. New 20-25 specialty chemicals ramp-up timelines uncertain.
Drug discovery & innovation timelines
MediumTNBC preliminary efficacy trials expected Q3 FY27; DME pilot March 2027. Trials are early-stage; timeline to clinical approval, manufacturing scale, and revenue uncertain. Drug discovery requires out-licensing, pharma partner selection, regulatory approvals.
Market sentiment & investor confidence
MediumConsolidated losses erode shareholder value. Q2 loss of ₹15.2 Cr and H1 loss of ₹34.6 Cr may concern value investors. Management did not commit to PAT positive timeline.
Management
Score 6/10. Samir Somaiya (Chairman) articulate on strategy and business model; candid on macro headwinds (monsoon, policy). Ashish Sinha (Deputy GM, IR) clear on financials. Some hedging on timelines; long-winded on feedstock dynamics. Beat Q2 chemicals guidance (₹204 vs ₹190 Cr). Debottlenecking progressing; grain distillery commissioned on time. H1 loss improving (₹34.6 Cr vs ₹57.6 Cr YoY). But consolidated profitability target missing; no clear path to breakeven disclosed.
1 · March 2027
DME pilot plant trial results (carbon dioxide to dimethyl ether conversion, LPG substitute)
2 · Q3 FY27 (Jul-Sep 2026)
TNBC triple-negative breast cancer molecule preliminary efficacy trial outcome; path to out-licensing
3 · Apr-Sep 2027
₹25 Cr debottlenecking capex to boost bio-chemicals capacity toward ₹240 Cr/qtr run-rate
The ₹240 Cr quarterly chemicals target by FY28 is ambitious and unproven; management offered no credible profitability timeline for the overall business.